Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction.
14. května 2026 aktualizováno: Mahmoud Hamada Mohamed, Benha University
Effects of Extracorporeal Shockwave Therapy Versus Pulsed Electromagnetic Field Therapy in Females With Sexual Dysfunction: a Randomized Controlled Trial
This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial designed to compare the effectiveness of extracorporeal shockwave therapy (ESWT) combined with pelvic floor muscle training (PFMT), pulsed electromagnetic field stimulation (PEMF) combined with PFMT, and PFMT alone in Females with sexual dysfunction.
Participants will be randomly allocated in a 1:1:1 ratio, and the study duration is 16 weeks, including an 8-week intervention period and an 8-week follow-up period.
Přehled studie
Postavení
Nábor
Podmínky
Detailní popis
Female sexual dysfunction is a multifactorial condition involving physiological, vascular, neuromuscular, and psychosocial components, and pelvic floor dysfunction and impaired genital blood flow are recognized contributing factors. Therefore, this trial integrates both neuromuscular rehabilitation and non-invasive energy-based modalities to target different underlying mechanisms of FSD.
A total of 90 women diagnosed with FSD based on a Female Sexual Function Index (FSFI) score < 26.55 will be recruited and randomly assigned in a 1:1:1 ratio to one of three groups. The ESWT + PFMT group will receive low-intensity radial extracorporeal shockwave therapy once weekly for 8 weeks, applied to the perineum and pelvic floor trigger points, in addition to a standardized pelvic floor muscle training program performed three times weekly under supervision. The PEMF + PFMT group will receive pulsed electromagnetic field stimulation three times weekly for 8 weeks, combined with the same standardized PFMT protocol. The PFMT-only group will perform identical supervised pelvic floor muscle training without adjunct device-based therapy.
Randomization will be performed using a computer-generated sequence with block randomization, and allocation will be ensured using sealed opaque envelopes. Outcome assessors will be blinded to group allocation to reduce assessment bias.
Typ studie
Intervenční
Zápis (Odhadovaný)
90
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: Mahmoud Hamada Mohamed Associate Professor, Ph.D
- Telefonní číslo: 01096968910
- E-mail: mahmoud.mohamed@fpt.bu.edu.eg
Studijní místa
-
-
-
Banī Suwayf, Egypt
- Nábor
- Outpatient clinic, faculty of Physical Therapy, Beni Suef University
-
Kontakt:
- Marwa Elsayed Mohamed Lecturer, Ph.D
- Telefonní číslo: 01141825442
- E-mail: Marwa.elsayed@pt.bsu.edu.eg
-
Kontakt:
- Marwa Elsayed Mohamed Lecturer, Ph.D
- E-mail: Marwa.elsayed@pt.bsu.edu.eg
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
Přijímá zdravé dobrovolníky
Ne
Popis
Inclusion Criteria:
- Female participants aged 20-50 years diagnosed with female sexual dysfunction (FSFI score <26.55), reporting symptoms of reduced sexual desire, arousal dysfunction, orgasmic dysfunction, or dyspareunia.
- Premenopausal women in a stable sexual relationship for at least 6 months and sexually active during the previous month.
- Symptoms persisting for at least 3 months before enrollment.
- Ability to understand study procedures and provide written informed consent.
- Willingness to refrain from initiating any additional treatment for sexual dysfunction during the study period
Exclusion Criteria:
- Pregnancy or planned pregnancy during the study period.
- Pelvic surgery within the previous 6 months.
- Active pelvic inflammatory disease, genital infection, or unexplained vaginal bleeding.
- Neurological disorders affecting pelvic floor or sexual function.
- Severe pelvic organ prolapse, severe urinary incontinence, or significant pelvic anatomical abnormalities.
- Current hormonal therapy or use of medications known to affect sexual function, including antidepressants or antipsychotics.
- Severe psychiatric disorders or cognitive impairment limiting participation.
- Menopause or perimenopausal status.
- Uncontrolled systemic diseases such as diabetes mellitus, hypertension, cardiovascular disease, or thyroid disorders.
- Presence of malignancy, pelvic radiation history, or severe chronic pelvic pain disorders.
- Contraindications to ESWT or PEMF including cardiac pacemakers or implanted electronic devices, coagulation disorders, anticoagulant therapy, epilepsy, or metal implants in the pelvic region.
- Current participation in another clinical trial or receipt of physiotherapy for sexual dysfunction within the previous 3 months.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: ESWT + PFMT
Participants will receive low-intensity extracorporeal shockwave therapy and participants will perform a standardized pelvic floor muscle training program
|
Extracorporeal shockwave therapy will be delivered using a low-intensity radial shockwave device, administered once weekly for 8 weeks, with each session delivering 1500-2000 shockwave pulses at an energy flux density of 0.05-0.10
mJ/mm² and a frequency of 5-8 Hz.
The application will target the perineum and pelvic floor trigger points using a standardized treatment probe with appropriate coupling gel to ensure optimal energy transmission.
Each session will last approximately 7 minutes, and intensity will be adjusted based on patient tolerance without exceeding the recommended energy threshold for soft tissue application
pelvic floor exercises will be performed for 45 minutes per day, three days per week, over an eight-week period.
Prior to beginning participant will be directed to void the bladder and be supine lying with flexed knees and mildly abducted hips.
She was then will be guided to contract the PFMs maximally, holding each contraction for 10 seconds.
This will be performed 15 times with a 10-second rest interval within contractions.
Each session will be consisted of three exercise sets, with each set performed for 15 minutes.
Home exercises were prescribed twice daily, providing a total of 45 minutes of training each day
|
|
Aktivní komparátor: PEMF + PFMT
Participants will receive pulsed electromagnetic stimulation combined with the same standardized pelvic floor muscle training program
|
pelvic floor exercises will be performed for 45 minutes per day, three days per week, over an eight-week period.
Prior to beginning participant will be directed to void the bladder and be supine lying with flexed knees and mildly abducted hips.
She was then will be guided to contract the PFMs maximally, holding each contraction for 10 seconds.
This will be performed 15 times with a 10-second rest interval within contractions.
Each session will be consisted of three exercise sets, with each set performed for 15 minutes.
Home exercises were prescribed twice daily, providing a total of 45 minutes of training each day
Pulsed electromagnetic field stimulation (PEMF) will be applied to the pelvic floor region for 20-minute sessions, three times weekly day after day for 8 consecutive weeks.
Stimulation parameters will include a frequency of 10 Hz, magnetic field intensity of 200 μT, and pulse duration of 250 μs.
Treatment sessions will be administered under therapist supervision with participants positioned comfortably in supine crook-lying.
|
|
Jiný: PFMT (Control)
Participants will receive a standardized pelvic floor muscle training program
|
pelvic floor exercises will be performed for 45 minutes per day, three days per week, over an eight-week period.
Prior to beginning participant will be directed to void the bladder and be supine lying with flexed knees and mildly abducted hips.
She was then will be guided to contract the PFMs maximally, holding each contraction for 10 seconds.
This will be performed 15 times with a 10-second rest interval within contractions.
Each session will be consisted of three exercise sets, with each set performed for 15 minutes.
Home exercises were prescribed twice daily, providing a total of 45 minutes of training each day
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Female Sexual Function Index (FSFI) Total Score
Časové okno: Baseline, Week 8. Week 16
|
Female sexual function will be assessed using the Female Sexual Function Index (FSFI), a validated self-reported 19-item questionnaire designed to evaluate six domains of female sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain.
Individual domain scores are calculated and summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function, while scores below 26.55 are considered indicative of female sexual dysfunction.
|
Baseline, Week 8. Week 16
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sexual Quality of Life Scale
Časové okno: Baseline, week 8, and week 16
|
Sexual quality of life will be assessed using the Sexual Quality of Life-Female Questionnaire (SQOL-F), a validated self-administered questionnaire designed to evaluate the impact of female sexual dysfunction on psychosocial well-being and intimate relationships.
The questionnaire consists of 18 items covering domains of sexual confidence, emotional well-being, relationship satisfaction, self-esteem, and psychosexual functioning.
Each item is scored on a 6-point Likert scale, and the total score is transformed to a 0-100 scale, with higher scores indicating better sexual quality of life.
|
Baseline, week 8, and week 16
|
|
Pelvic floor muscle strength
Časové okno: Baseline, week 6 and week 16
|
Pelvic floor muscle strength will be objectively assessed before and after the intervention using the XFT-0010 Pelvic Floor Assessment System.
The system consists of an appropriately sized intravaginal pressure probe connected to the main recording unit via a flexible catheter, enabling quantitative measurement of pelvic floor muscle contraction strength.
Participants will be assessed in the crook-lying position under standardized conditions and instructed to perform three maximal voluntary pelvic floor muscle contractions, each separated by a standardized rest interval to minimize fatigue.
The highest recorded contraction value will be used for statistical analysis.
|
Baseline, week 6 and week 16
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Spolupracovníci
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
14. května 2026
Primární dokončení (Odhadovaný)
15. prosince 2026
Dokončení studie (Odhadovaný)
15. ledna 2027
Termíny zápisu do studia
První předloženo
7. května 2026
První předloženo, které splnilo kritéria kontroly kvality
7. května 2026
První zveřejněno (Aktuální)
13. května 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
18. května 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
14. května 2026
Naposledy ověřeno
1. května 2026
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- ESWT VS PEMF in FSD 2026
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NEROZHODNÝ
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na low-intensity extracorporeal shockwave therapy
-
KTO Karatay UniversityDokončenoBolest | Nemoci nohou | Plantární fasciitidaKrocan